Table 1.
Patient characteristics.
| Number of patients (%) | |
|---|---|
| Sex | |
| Male | 53 (58) |
| Female | 39 (42) |
| Median age (years) | 59 (range 21–86) |
| FAB classification | |
| M0 | 9 (10) |
| M1 | 22 (24) |
| M2 | 16 (17) |
| M3 | 6 (7) |
| M4 | 17 (18) |
| M5 | 21 (23) |
| Not classified | 1 (1) |
| WHO classification | |
| AML with recurrent genetic abnormalities | 55 (60) |
| AML with myelodysplasia-related changes | 11 (12) |
| Therapy-related myeloid neoplasms | 3 (2) |
| Myeloid neoplasms with germline predisposition | 0 (0) |
| AML. not otherwise specified | 24 (26) |
| Primary/secondary AML | |
| Primary | 70 (76) |
| Secondary | 22 (24) |
| Blood count (median) | |
| WBC (G/L) | 56.9 (range 4.6–448.3) |
| Hb (g/dl) | 8.6 (range 4.4–12.9) |
| Plt (G/L) | 43.5 (range 6–252) |
| NCCN risk score distribution | |
| Favorable | 33 (36) |
| Intermediate | 36 (39) |
| Poor | 16 (17) |
| Not classified | 7 (8) |
| Genetic abberations | |
| t(15;17) | 6 (6) |
| inv(16) | 4 (4) |
| FLT3-ITD | 28 (26) |
| FLT3-TKD | 5 (5) |
| NPM1 | 24 (21) |
| CEBPA | 6 (6) |
| MLL-AF9 | 2 (2) |
| IDH 2 | 6 (6) |
AML acute myeloid leukemia; FAB French-American-British; WBC white blood count; Hb hemoglobin; Plt thrombocytes; NCCN National Comprehensive Cancer Network.